NTLA · Intellia Therapeutics, Inc.

Intellia Therapeutics reported first quarter 2026 financial results, highlighting significant clinical and regulatory progress. The company announced positive topline Phase 3 data for lonvo-z in hereditary angioedema (HAE), meeting the primary endpoint with an 87% reduction in attacks versus placebo (p<0.0001) and all key secondary endpoints. A rolling BLA submission has been initiated, with completion expected in the second half of 2026, targeting a U.S. launch in the first half of 2027. Additionally, the FDA lifted clinical holds on the MAGNITUDE and MAGNITUDE-2 Phase 3 trials of nex-z in ATTR amyloidosis, allowing patient screening to resume. Financially, the company ended Q1 with $517.2 million in cash, cash equivalents, and marketable securities, and subsequently raised approximately $207 million in gross proceeds from an underwritten public offering in April 2026. Management expects existing cash resources to fund operations at least into 2028, well beyond the anticipated lonvo-z launch. Net loss narrowed to $96.2 million from $114.3 million in the prior year quarter, driven by lower R&D expenses ($80.7 million vs. $108.4 million) due to reduced costs for research materials and contracted services. Collaboration revenue was $15.0 million, slightly down from $16.6 million. G&A expenses increased to $34.8 million from $29.0 million, reflecting commercial infrastructure buildout. The company plans to complete patient enrollment in MAGNITUDE-2 in the second half of 2026 and will present additional HAELO data at the EAACI Congress in June.